Andrew Herxheimer, Barbara Mintzes ß See related articles pages 455 and 489 miscoding
and flawed analyses by regulators led to an underestimation of the risk of suicidal behaviour …

A report from the British Medicines and Healthcare Products Regulatory Agency (MHRA) of
December 10, 2003, recommends cessation of use of all antidepressants except fluoxetine …

In June 2003, the Medicine and Healthcare Products Regulatory Agency of the British
Department of Health warned physicians to avoid the off-label use of paroxetine, a selective …

The present controversy about the use of selective serotonin re-uptake inhibitors in
paediatric patients has been the subject of many publications. This article summarises the …

ANTIDEPRESSANTS IN CHILDREN of suicidal behaviour associated with antidepressant
drugs. So, in the light of the evidence for a statistically significant but clinically insignificant …

We were interested in the letter by Hengartner and Plöderl [1] which was covered by the
press in the United Kingdom. The issue of potential suicide risk in relation to antidepressant …

In June last year, the committee on safety of medicines (CSM) advised against the use of
paroxetine in depressed children and adolescents. This was subsequently followed by a …

SUICIDE IS THE THIRD leading cause of death in the United States at ages 10 through 24
years. 1 Major depressive disorder and depressive phases of bipolar I and II disorders are …

The data supporting the use of “antidepressants” in children and adolescents is largely
unavailable. Academic publications give a different picture as regards benefits and harms to …

Six months after the UK banned antidepressant drugs for children, Health Canada has
issued a warning that using 7 of the medications may make patients worse. Patients of all …